FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282964162> ?p ?o ?g. }

• W4282964162 endingPage "e761" @default.
• W4282964162 startingPage "e751" @default.
• W4282964162 abstract "Background and Objective To characterize trends in antiseizure medication (ASM) fills and total prescription costs in people with epilepsy. Methods This was a retrospective cohort study of beneficiaries with epilepsy (ASM, plus ICD codes) in a 20% random Medicare sample, with continuous Fee-For-Service coverage (Parts A, B, and D) in 2008–2018. We summed the number of pill days and costs (adjusted to 2018 dollars) per person-year for each ASM. ASMs were categorized into brand vs generic, first vs newer generation, and enzyme inducers vs noninducers. Results There were 77,000–133,000 beneficiaries with epilepsy per year. The most common ASM was phenytoin in 2008, which shifted to levetiracetam in 2018 (2008: phenytoin 25%, levetiracetam 14%; 2018: phenytoin 9%, levetiracetam 27%). Brand name (2008: 56%; 2018: 14%), first-generation (2008: 55%; 2018: 32%), and enzyme-inducing ASMs (2008: 44%; 2018: 24%) each decreased over time as a proportion of pill days. The number of brand pill days per person-year initially decreased (e.g., 2008: 250; 2009: 121; 2010: 96) but then plateaued (2013–2018: between 66 and 69) given a notable increase in lacosamide pill days per person (2008: 0; 2018: 20). Total brand name costs per year initially decreased 2008–2010 (2008: $150 million; 2010: $72 million) but then increased after 2010 (2018: $256 million). In 2018, brand name ASMs represented 79% of costs despite representing only 14% of pill days, a 1-year pill supply became 277% more expensive for brand name medications but 42% less expensive for generic medications over time (2008: brand ∼$2,800 vs generic ∼$800; 2018: brand ∼$10,700 vs generic ∼$460), and many common brand name ASMs cost approximately 10-fold more per pill day than their generic equivalents. Discussion First-generation and enzyme-inducing ASMs waned from 2008 to 2018. Although brand name ASMs initially waned translating into lower costs and potentially higher value care, after 2010, brand name costs markedly increased because of increasing use of lacosamide plus a 277% increase in per-pill cost of brand name ASMs. Brand name ASMs represented a minority of prescriptions, but the majority of costs." @default.
• W4282964162 created "2022-06-17" @default.
• W4282964162 creator A5008465953 @default.
• W4282964162 creator A5017587509 @default.
• W4282964162 creator A5020983805 @default.
• W4282964162 creator A5028786045 @default.
• W4282964162 creator A5045867300 @default.
• W4282964162 creator A5083782478 @default.
• W4282964162 date "2022-08-23" @default.
• W4282964162 modified "2023-10-16" @default.
• W4282964162 title "Changes in the Use of Brand Name and Generic Medications and Total Prescription Cost Among Medicare Beneficiaries With Epilepsy" @default.
• W4282964162 cites W1037854419 @default.
• W4282964162 cites W1581120810 @default.
• W4282964162 cites W16434660 @default.
• W4282964162 cites W1899072698 @default.
• W4282964162 cites W1966601175 @default.
• W4282964162 cites W1970811928 @default.
• W4282964162 cites W1971500956 @default.
• W4282964162 cites W1978437325 @default.
• W4282964162 cites W1996164910 @default.
• W4282964162 cites W2014290441 @default.
• W4282964162 cites W2016515948 @default.
• W4282964162 cites W2019178697 @default.
• W4282964162 cites W2032816560 @default.
• W4282964162 cites W2049338671 @default.
• W4282964162 cites W2077618811 @default.
• W4282964162 cites W2123177504 @default.
• W4282964162 cites W2124698838 @default.
• W4282964162 cites W2132687986 @default.
• W4282964162 cites W2136913469 @default.
• W4282964162 cites W2143243043 @default.
• W4282964162 cites W2149187403 @default.
• W4282964162 cites W2150588411 @default.
• W4282964162 cites W2154914124 @default.
• W4282964162 cites W2230640864 @default.
• W4282964162 cites W2303801524 @default.
• W4282964162 cites W2463498831 @default.
• W4282964162 cites W2526135678 @default.
• W4282964162 cites W2527306442 @default.
• W4282964162 cites W2556613236 @default.
• W4282964162 cites W2563892612 @default.
• W4282964162 cites W2586875536 @default.
• W4282964162 cites W2726071308 @default.
• W4282964162 cites W2765457051 @default.
• W4282964162 cites W2766751362 @default.
• W4282964162 cites W2805473242 @default.
• W4282964162 cites W2808405323 @default.
• W4282964162 cites W2916334037 @default.
• W4282964162 cites W2938514096 @default.
• W4282964162 cites W2950024036 @default.
• W4282964162 cites W2980945862 @default.
• W4282964162 cites W3008147607 @default.
• W4282964162 cites W3039237517 @default.
• W4282964162 cites W3135138620 @default.
• W4282964162 cites W3182040665 @default.
• W4282964162 cites W3196804517 @default.
• W4282964162 cites W4200360228 @default.
• W4282964162 cites W4237465600 @default.
• W4282964162 doi "https://doi.org/10.1212/wnl.0000000000200779" @default.
• W4282964162 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35705496" @default.
• W4282964162 hasPublicationYear "2022" @default.
• W4282964162 type Work @default.
• W4282964162 citedByCount "8" @default.
• W4282964162 countsByYear W42829641622022 @default.
• W4282964162 countsByYear W42829641622023 @default.
• W4282964162 crossrefType "journal-article" @default.
• W4282964162 hasAuthorship W4282964162A5008465953 @default.
• W4282964162 hasAuthorship W4282964162A5017587509 @default.
• W4282964162 hasAuthorship W4282964162A5020983805 @default.
• W4282964162 hasAuthorship W4282964162A5028786045 @default.
• W4282964162 hasAuthorship W4282964162A5045867300 @default.
• W4282964162 hasAuthorship W4282964162A5083782478 @default.
• W4282964162 hasBestOaLocation W42829641622 @default.
• W4282964162 hasConcept C112698675 @default.
• W4282964162 hasConcept C118552586 @default.
• W4282964162 hasConcept C144133560 @default.
• W4282964162 hasConcept C187212893 @default.
• W4282964162 hasConcept C2426938 @default.
• W4282964162 hasConcept C2777332695 @default.
• W4282964162 hasConcept C2778139780 @default.
• W4282964162 hasConcept C2778186239 @default.
• W4282964162 hasConcept C2992181568 @default.
• W4282964162 hasConcept C71924100 @default.
• W4282964162 hasConcept C81603835 @default.
• W4282964162 hasConcept C98274493 @default.
• W4282964162 hasConceptScore W4282964162C112698675 @default.
• W4282964162 hasConceptScore W4282964162C118552586 @default.
• W4282964162 hasConceptScore W4282964162C144133560 @default.
• W4282964162 hasConceptScore W4282964162C187212893 @default.
• W4282964162 hasConceptScore W4282964162C2426938 @default.
• W4282964162 hasConceptScore W4282964162C2777332695 @default.
• W4282964162 hasConceptScore W4282964162C2778139780 @default.
• W4282964162 hasConceptScore W4282964162C2778186239 @default.
• W4282964162 hasConceptScore W4282964162C2992181568 @default.
• W4282964162 hasConceptScore W4282964162C71924100 @default.
• W4282964162 hasConceptScore W4282964162C81603835 @default.
• W4282964162 hasConceptScore W4282964162C98274493 @default.
• W4282964162 hasIssue "8" @default.

• next